Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated July 6, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 67,900 people across 80 countries. The filing details transactions executed under a programme initiated on May 6, 2026, which is part of a broader authorization to repurchase up to DKK 15 billion in shares over a 12-month period starting February 4, 2026.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities rather than operational financial performance. Key metrics include:
- Share Repurchase Programme Cap: DKK 15 billion (12-month period from Feb 4, 2026).
- Specific Programme Cap (May 6, 2026): DKK 11,200,000,010.45.
- Total Repurchased (Feb 4 - July 3, 2026): 23,009,179 B shares.
- Total Value Repurchased (Feb 4 - July 3, 2026): DKK 6,219,775,971.
- Average Purchase Price (Feb 4 - July 3, 2026): DKK 270.32 per B share.
- Treasury Shares Held: 40,194,480 B shares (0.9% of share capital).
- Total Share Capital: 4,465,000,000 shares (including treasury shares).
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Recent Transactions
Since the last announcement on June 29, 2026, the company executed five transactions between June 30 and July 3, 2026. The average purchase price for these recent transactions ranged from DKK 314.24 to DKK 326.71, indicating a rising share price trend during this specific window.
| Date | Shares Purchased | Avg Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| 30 June 2026 | 200,000 | 314.24 | 62,847,300 |
| 1 July 2026 | 200,000 | 318.15 | 63,630,624 |
| 2 July 2026 | 200,000 | 320.42 | 64,083,705 |
| 3 July 2026 | 200,000 | 325.11 | 65,022,718 |
| 3 July 2026 | 200,000 | 326.71 | 65,342,713 |
Accumulated purchases under the specific May 6 programme reached 8,250,000 shares with a total value of DKK 2,419,775,981 as of July 3, 2026.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the DKK 15 billion limit during the 12-month period beginning February 4, 2026. The company remains committed to its purpose of defeating serious chronic diseases, particularly in diabetes.
Risks and Contingencies: The filing does not disclose specific new risks or contingencies. It notes that the repurchase programme is conducted in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 15 billion repurchase authorization (approx. DKK 8.78 billion remaining as of July 3, 2026).
- Confirm the current market price of Novo Nordisk B shares relative to the recent average purchase price of DKK 326.71.
- Review the full list of transactions on the company's official website (novonordisk.com) for updates post-July 3, 2026.
- Check the latest Form 20-F or quarterly reports for operational financial metrics (revenue, earnings) not included in this 6-K.